Altimmune inc (ALT) - News Archive

AI-Based Pathology Unveils Promising Results in Liver Fibrosis from Pemvidutide IMPACT Phase 2b Trial The field of hepatic diseases has long sought innovative approaches to tackle the persistent challenge of liver fibro...

Recent developments in the treatment of non-alcoholic steatohepatitis (NASH) highlight the increasing potential of emerging therapies. Notably, Altimmune Inc. is poised to present compelling findings from its Phase 2b c...

The pharmaceutical industry is a dynamic and competitive arena, with significant implications for investors and stakeholders. Altimmune, Inc. (NASDAQ: ALT), a notable entity within this sector, has recently come under s...

In a noteworthy development for investors, Bragar Eagel & Squire, P.C., a prominent shareholder rights law firm, has issued a reminder regarding ongoing class action lawsuits against Altimmune, Inc. (NASDAQ: ALT) and Se...

Analyzing the Current LandscapeIn recent developments, Altimmune, Inc. (NASDAQ: ALT) has found itself navigating turbulent waters. The company, known for its innovative approaches in the biopharmaceutical sector, has re...

Altimmune Inc. a biopharmaceutical company focused on developing innovative products to treat liver diseases and other metabolic disorders, recently presented pivotal findings at The Liver Meeting 2024. These findings h...

In an announcement poised to stir considerable interest within the scientific and financial communities, Altimmune Inc. a nascent titan in the realm of biopharmaceuticals, hath proclaimed the successful completion of su...

Altimmune Presents Promising Pemvidutide Data at EASD Annual Meeting: A Breakthrough in Obesity and MASH TreatmentAltimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, has garnered significant atten...

Revolutionary Breakthrough in Treating MASLD: Pemvidutide Shows Promising Results in Clinical StudyIn the rapidly evolving field of metabolic diseases, the recent publication of a clinical study by Altimmune in the pres...

(paragraph 1)Altimmune Inc, a clinical-stage biopharmaceutical company, has experienced a significant sell-off in its shares this year. With a performance that falls short of the broader market by 15.44%, investors and...

Altimmune Mourns Passing of Chief Financial Officer, Richard EisenstadtFacts:- Altimmune, Inc., a clinical-stage biopharmaceutical company, has announced the unexpected passing of its Chief Financial Officer, Richard Ei...

for CSIMarket.com In recent years, the global obesity epidemic has prompted extensive research into new and effective treatment options. Altimmune, Inc., a clinical-stage biopharmaceutical company, presented compelling...

The incidence of cardiovascular diseases (CVD) and metabolic dysfunction-associated steatohepatitis (MASH) has been rapidly escalating globally, necessitating the urgent need for novel therapeutic interventions. Altimmu...

Altimmune, a leading clinical-stage biopharmaceutical company, has recently announced its plans to present clinical data on pemvidutide at the American Diabetes Association (ADA) 84th Scientific Sessions. This investiga...

Metabolic Dysfunction-Associated Steatohepatitis (MASH) is a serious liver disease characterized by inflammation and fatty degeneration, commonly seen in individuals with metabolic disorders such as obesity and diabetes...

In a shocking turn of events, the medical community is mourning the untimely demise of Dr. Stephen Harrison, a brilliant mind and a remarkable innovator in the field of medicine. Altimmune, a biopharmaceutical company a...

Altimmune Inc. Reports Positive Results from 48-Week Phase 2 Obesity Trial of PemvidutideAltimmune Inc., a clinical-stage biopharmaceutical company, has announced positive topline results from its MOMENTUM Phase 2 trial...